In last week’s post, we reviewed Pluymaekers et al (1), a randomized control trial from the Netherlands on early or delayed cardioversion for recent-onset atrial fibrillation (AF). In this post, we will analyze our practice in the U.S. and discuss some of the arguments for and against cardioversion in the Read more…
A recent NEJM article, “Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation” by Pluymaekers et al has reinvigorated debate in the blogosphere, academia conference halls, and podcast-dom over management of recent-onset atrial fibrillation (AF) (1,2,3). Prior studies have demonstrated that cardioversion for recent-onset atrial fibrillation (typically defined by a duration Read more…
by Sana Kathawala, MD MBA It’s a quiet day in the ED. You’re twiddling your thumbs wondering whether you should get a second cup of coffee to keep awake when the notification phone rings. “68-year-old male with history of diabetes, hypertension, and ESRD with witnessed syncope after hemodialysis earlier today. Read more…